ProfileGDS5678 / 1416441_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 85% 89% 92% 87% 87% 86% 89% 90% 87% 85% 88% 85% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6677887
GSM967853U87-EV human glioblastoma xenograft - Control 26.4207585
GSM967854U87-EV human glioblastoma xenograft - Control 37.0543989
GSM967855U87-EV human glioblastoma xenograft - Control 47.8880292
GSM967856U87-EV human glioblastoma xenograft - Control 56.7505287
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4019787
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.3769886
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9153389
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0931490
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.7717387
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3571685
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.990688
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3146685
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3119285